Amneal Celebrates FDA Approvals For Generic Namzaric And Afinitor Disperz

Also, Tentative Approval For Off-Patent Rival To Xifaxan Due To Ongoing Litigation

Amneal builds on its affordable medicines business with three FDA approvals – two final and one tentative – for generic rivals referencing AbbVie’s Namzaric, Novartis’ Afinitor Disperz, and Bausch Health’s Xifaxan.

Stamp saying approved
(Shutterstock)

Amneal has snatched US Food and Drug Administration approval for and launched its generic rival to AbbVie’s Namzaric (memantine/donepezil) extended-release capsules, with the agency also granting 180-day market exclusivity.

The drug, which was approved in 14mg/10mg and 28mg/10mg doses, is indicated to treat moderate to severe dementia due the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

EU Industry Welcomes Generics Exemption From US Tariffs

 
• By 

The European generics industry has welcomed news that generic medicines will be exempt from tariffs under the latest EU-US trade agreement.

‘It Validates Adalvo‘ – CEO Anil Okay Talks EQT Takeover

 
• By 

In the wake of a major transaction that saw private-equity firm EQT take control of Alvo group B2B business Adalvo, CEO Anil Okay talks to Generics Bulletin about what the deal means for Adalvo and how it is planning to expand in future.

Viatris Locks Cipla Out Of Generic Yupelri Market Until 2039

 
• By 

Cipla has reached a settlement with Theravance Biopharma and Viatris regarding its proposed generic version of Yupelri (revefenacin) once-daily nebulized inhalation solution. Under the agreement, Cipla will not introduce its product into the US market prior to April 2039.

Vanda Slams FDA ‘Generic Bias’ As It Again Seeks To Undo Hetlioz ANDA Approvals

 
• By 

In its latest attempt to curtail generic versions of Hetlioz, Vanda Pharmaceuticals has called on US FDA commissioner Marty Makary to reverse a previous agency decision upholding two ANDA approvals, claiming an “unacceptable culture of bias toward approving generic drugs” at the FDA.

More from Generics Bulletin

Aeon Expects Imminent Data On Botox Biosimilar

 
• By 

Aeon Biopharma says it expects to complete primary structure and select functional analyses for its ABP-450 proposed biosimilar to Botox by the end of the current quarter, ahead of a meeting with the FDA in late 2025 to discuss next steps.

ANI Raises Guidance Once More But Admits Generics Sales Will Soften In H2

 
• By 

ANI insisted that it would continue to invest in Generics R&D to keep up a cadence of launches, following another strong quarter on the back of generic prucalopride and its Cortrophin Gel.

Viatris Locks Cipla Out Of Generic Yupelri Market Until 2039

 
• By 

Cipla has reached a settlement with Theravance Biopharma and Viatris regarding its proposed generic version of Yupelri (revefenacin) once-daily nebulized inhalation solution. Under the agreement, Cipla will not introduce its product into the US market prior to April 2039.